Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
52 studies found for:    Open Studies | "hospital of central connecticut"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "hospital of central connecticut"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Connect® MM- The Multiple Myeloma Disease Registry
Condition: Multiple Myeloma
Intervention:
2 Recruiting Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Condition: Chronic Lymphocytic Leukemia
Intervention:
3 Recruiting Cardiovascular Inflammation Reduction Trial
Condition: Cardiovascular Disease
Interventions: Drug: Methotrexate;   Drug: Placebo
4 Recruiting Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery
Conditions: Stage IB Breast Cancer;   Stage II Breast Cancer
Interventions: Radiation: regional nodal XRT;   Radiation: chestwall XRT;   Radiation: WBI
5 Recruiting Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer
Conditions: Endometrial Adenocarcinoma;   Endometrial Clear Cell Carcinoma;   Endometrial Papillary Serous Carcinoma;   Recurrent Endometrial Carcinoma;   Stage IIIA Endometrial Carcinoma;   Stage IIIB Endometrial Carcinoma;   Stage IIIC Endometrial Carcinoma;   Stage IVA Endometrial Carcinoma;   Stage IVB Endometrial Carcinoma
Interventions: Drug: paclitaxel;   Drug: carboplatin;   Drug: metformin hydrochloride;   Other: placebo;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment;   Other: questionnaire administration
6 Recruiting Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer
Conditions: Endometrial Adenocarcinoma;   Endometrial Clear Cell Adenocarcinoma;   Endometrial Serous Adenocarcinoma;   Recurrent Uterine Corpus Carcinoma
Interventions: Drug: Trametinib;   Drug: Akt Inhibitor GSK2141795;   Other: Laboratory Biomarker Analysis
7 Recruiting Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Vulva
Conditions: Squamous Cell Carcinoma of the Vulva;   Stage IIIA Vulvar Cancer;   Stage IIIB Vulvar Cancer;   Stage IIIC Vulvar Cancer;   Stage IVA Vulvar Cancer
Interventions: Radiation: intensity-modulated radiation therapy;   Drug: gemcitabine hydrochloride;   Drug: cisplatin;   Procedure: therapeutic conventional surgery
8 Recruiting Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
Conditions: Recurrent Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Biological: Ipilimumab;   Biological: Recombinant Interferon Alfa-2b;   Other: Quality-of-Life Assessment
9 Recruiting Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
Conditions: Malignant Ovarian Mixed Epithelial Tumor;   Ovarian Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Drug: Paclitaxel;   Drug: Docetaxel;   Drug: Carboplatin;   Biological: Bevacizumab;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
10 Recruiting Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Cell Carcinoma;   Cervical Squamous Cell Carcinoma;   Stage IA Cervical Cancer;   Stage IB Cervical Cancer;   Stage IIA Cervical Cancer
Interventions: Drug: cisplatin;   Radiation: external beam radiation therapy;   Radiation: intensity-modulated radiation therapy;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
11 Recruiting Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer
Conditions: Endometrial Clear Cell Adenocarcinoma;   Ovarian Clear Cell Cystadenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Recurrent Uterine Corpus Carcinoma
Interventions: Drug: Dasatinib;   Other: Laboratory Biomarker Analysis
12 Recruiting Diet and Physical Activity Change or Usual Care in Improving Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Primary Peritoneal Cavity Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Primary Peritoneal Cavity Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Primary Peritoneal Cavity Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer
Interventions: Behavioral: behavioral dietary intervention;   Behavioral: exercise intervention;   Other: counseling intervention;   Other: educational intervention;   Behavioral: compliance monitoring;   Other: questionnaire administration;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
13 Recruiting Methotrexate or Dactinomycin in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia
Conditions: Gestational Trophoblastic Tumor;   Hydatidiform Mole;   Low Risk Metastatic Gestational Trophoblastic Tumor;   Uterine Choriocarcinoma
Interventions: Drug: leucovorin calcium;   Biological: dactinomycin;   Drug: methotrexate;   Procedure: quality-of-life assessment
14 Recruiting Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: clofarabine;   Drug: daunorubicin hydrochloride;   Other: clinical observation;   Drug: cytarabine;   Drug: decitabine;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment;   Other: questionnaire administration
15 Recruiting Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Cell Carcinoma;   Cervical Squamous Cell Carcinoma;   Chemotherapeutic Agent Toxicity;   Cognitive/Functional Effects;   Psychosocial Effects of Cancer and Its Treatment;   Radiation Toxicity;   Sexuality and Reproductive Issues;   Stage IB Cervical Cancer;   Stage IIA Cervical Cancer;   Stage IIB Cervical Cancer;   Stage III Cervical Cancer;   Stage IVA Cervical Cancer
Interventions: Drug: cisplatin;   Drug: paclitaxel;   Drug: carboplatin;   Radiation: external beam radiation therapy;   Radiation: brachytherapy;   Other: quality-of-life assessment
16 Recruiting Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer
Conditions: Ovarian Clear Cell Cystadenocarcinoma;   Stage III Ovarian Cancer;   Stage IV Ovarian Cancer
Interventions: Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Temsirolimus;   Drug: Docetaxel;   Other: Laboratory Biomarker Analysis
17 Recruiting Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer
Condition: Endometrial Cancer
Interventions: Drug: Carboplatin/Paclitaxel;   Drug: Trastuzumab
18 Recruiting Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors
Condition: Ovarian Stromal Cancer
Interventions: Drug: paclitaxel;   Drug: carboplatin;   Biological: bleomycin sulfate;   Drug: etoposide phosphate;   Drug: cisplatin
19 Recruiting Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy
Condition: Ductal Breast Carcinoma In Situ
Interventions: Biological: Trastuzumab;   Radiation: Whole Breast Irradiation;   Other: Laboratory Biomarker Analysis
20 Recruiting Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma
Conditions: Stage II Contiguous Adult Diffuse Large Cell Lymphoma;   Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma
Interventions: Drug: Lenalidomide;   Biological: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Vincristine Sulfate;   Drug: Prednisone;   Other: Laboratory Biomarker Analysis

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years